BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to seven newly-hired employees, covering a total of 48,000 shares of common stock. The RSUs were awarded on May 1, 2025 as employment inducements and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years in equal annual installments, beginning one year from the grant date, contingent on continued employment. These grants are governed by BioCryst's Inducement Equity Incentive Plan and individual RSU agreements.
BioCryst Pharmaceuticals (BCRX) ha assegnato unità azionarie vincolate (RSU) a sette nuovi dipendenti, per un totale di 48.000 azioni ordinarie. Le RSU sono state concesse il 1 maggio 2025 come incentivo all'assunzione e sono conformi alla Regola 5635(c)(4) del Nasdaq. Le RSU matureranno in quattro anni con rate annuali uguali, a partire da un anno dalla data di assegnazione, a condizione che il rapporto di lavoro continui. Questi incentivi sono regolati dal Piano di Incentivi Azionari di BioCryst e dai singoli accordi RSU.
BioCryst Pharmaceuticals (BCRX) ha otorgado unidades de acciones restringidas (RSU) a siete empleados recién contratados, cubriendo un total de 48,000 acciones comunes. Las RSU se concedieron el 1 de mayo de 2025 como incentivos de contratación y cumplen con la Regla 5635(c)(4) de Nasdaq. Las RSU se consolidarán durante cuatro años en cuotas anuales iguales, comenzando un año después de la fecha de concesión, condicionado a la continuidad del empleo. Estas concesiones están regidas por el Plan de Incentivos de Capital por Inducción de BioCryst y los acuerdos individuales de RSU.
BioCryst Pharmaceuticals (BCRX)는 신규 채용 직원 7명에게 총 48,000주의 보통주에 해당하는 제한 주식 단위(RSU)를 부여했습니다. RSU는 2025년 5월 1일에 고용 유인책으로 수여되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. RSU는 부여일로부터 1년 후부터 매년 동일한 비율로 4년간 베스팅되며, 계속 고용 조건에 따라 지급됩니다. 이 부여는 BioCryst의 유인 주식 인센티브 계획과 개별 RSU 계약에 의해 관리됩니다.
BioCryst Pharmaceuticals (BCRX) a accordé des unités d'actions restreintes (RSU) à sept nouveaux employés, couvrant un total de 48 000 actions ordinaires. Les RSU ont été attribuées le 1er mai 2025 en tant qu'incitations à l'embauche et sont conformes à la règle Nasdaq 5635(c)(4). Les RSU seront acquises sur une période de quatre ans par versements annuels égaux, à partir d'un an après la date d'attribution, sous réserve de la poursuite de l'emploi. Ces attributions sont régies par le Plan d'Incitation en Actions d'Induction de BioCryst et les accords RSU individuels.
BioCryst Pharmaceuticals (BCRX) hat beschränkte Aktieneinheiten (RSUs) an sieben neu eingestellte Mitarbeiter vergeben, die insgesamt 48.000 Stammaktien abdecken. Die RSUs wurden am 1. Mai 2025 als Anreiz zur Einstellung gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs werden über vier Jahre in gleichen jährlichen Raten ausgegeben, beginnend ein Jahr nach dem Gewährungsdatum, vorbehaltlich einer fortgesetzten Anstellung. Diese Zuteilungen unterliegen dem Inducement Equity Incentive Plan von BioCryst und den individuellen RSU-Vereinbarungen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 48,000 shares of BioCryst common stock. The RSUs were granted as of May 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
What is the vesting schedule for BCRX's May 2025 RSU grants?
How many shares of BCRX stock were granted as RSUs in May 2025?
What is the purpose of BCRX's RSU grants announced in May 2025?
Under which plan were BCRX's May 2025 RSU grants issued?
